Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis.

ABSTRACT: Background: Randomized clinical trials (RCTs) of anticancer drugs without active comparators in patients who have exhausted standard of care treatment options are debated. We aimed to quantify the safety and the efficacy of anticancer drugs in advanced cancer patients who have exhausted standard of care treatments from RCTs without active comparators.Methods: This systematic review and meta-analysis was conducted according to preferred reporting Items for systematic review and Meta-Analyses (PRISMA) guidelines (CRD42021243968). A systematic literature search of English language publications from January 1, 2000, to January 7, 2021, was performed using MEDLINE (PubMed). Eligible trials included all RCTs evaluating anticancer drugs in adult patients with advanced solid tumors w

SUBMITTER: Moreau Bachelard C 

PROVIDER: S-EPMC8548931 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature